The American Journal of Managed Care

Analysis Supports Concurrent Plasma NGS, Tissue Testing for NSCLC

Integrating plasma next-generation sequencing (NGS) alongside tissue testing when determining lung cancer diagnosis may improve outcomes for patients. Carrying out plasma next-generation sequencing ...
Business Wire

FDA Approves First NGS-Based Companion Diagnostic to Aid in Selecting Non-Small Cell Lung Cancer Patients with HER2 (ERBB2) Activating Mutations (SNVs & Exon 20 Insertions) for ...

CARLSBAD, Calif.--(BUSINESS WIRE)--The U.S. Food and Drug Administration (FDA) has granted premarket approval to Thermo Fisher Scientific’s Oncomine Dx Target Test as a companion diagnostic (CDx) to ...
The American Journal of Managed Care

Inequalities Within and Between Practices Contribute to NGS Testing Disparities in NSCLC

A study presented at the American Society of Clinical Oncology Annual Meeting found practice- and provider-level racial and ethnic inequities in rates of next-generation sequencing (NGS) testing for ...
Labroots

RET aberrations and EGFR exon 20 insertions testing in the complex NSCLC biomarker landscape

In this presentation the speaker will discuss latest developments in NSCLC precision therapy and biomarker landscape, and importance of NGS in NSCLC biomarker testing. He will review the NSCLC ...
Wane

ChromaCode Announces Publication Highlighting Advancements in HDPCR NSCLC Assay Performance, Demonstrating Advantages Over Next Generation Sequencing in Enabling Timely Results ...

CARLSBAD, Calif., Nov. 14, 2023 /PRNewswire/ -- ChromaCode, Inc., a pioneering genomics multiplexing platform company developing accessible and affordable laboratory-based solutions, today announced ...
Nasdaq

Biocept to Collaborate with Quest Diagnostics to Provide Advanced NGS-Based Liquid Biopsy Testing for Patients with Lung Cancer

SAN DIEGO--(BUSINESS WIRE)-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced a collaboration with Quest Diagnostics (NYSE: DGX) ...
Hosted on MSN

FDA approves Thermo Fisher’s diagnostic test for new NSCLC treatment

The US Food and Drug Administration (FDA) has granted approval for Thermo Fisher Scientific's Oncomine Dx Target Test as a treatment for non-small cell lung cancer (NSCLC). The test serves as a ...